Joshua Schafer
CIK: 0001945557
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Feb 3, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Sale(S)Direct10.5K shares at avg. $9.19$97K - Jan 31, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Exercise(M)Direct35.3K shares- - Jan 30, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Sale(S)Direct3.4K shares at avg. $8.83$30K - Jan 30, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Exercise(M)Direct11.3K shares- - Jan 29, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
75K shares- - Jan 29, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Award(A)DirectRestricted Stock Unit
37.5K shares- - Feb 13, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Sale(S)Direct10.5K shares at avg. $7.86$83K - Jan 31, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Exercise(M)Direct35.3K shares- - Jan 30, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
68K shares- - Jan 30, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Award(A)DirectRestricted Stock Unit
34K shares- - Dec 31, 2024SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Award(A)Direct209.8K shares- - Dec 23, 2024SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Award(A)Direct209.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 3, 2026 |  ZVRA ZEVRA THERAPEUTICS, INC. | Sale(S) | 10,500 | $9.19 | $96,500 | Direct |
| Jan 31, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Exercise(M) | 35,334 | - | $0 | Direct |
| Jan 30, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Sale(S) | 3,375 | $8.83 | $29,800 | Direct |
| Jan 30, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Exercise(M) | 11,333 | - | $0 | Direct |
| Jan 29, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 75,000 | - | - | Direct |
| Jan 29, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Award(A) Restricted Stock Unit | 37,500 | - | - | Direct |
| Feb 13, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Sale(S) | 10,500 | $7.86 | $82,527 | Direct |
| Jan 31, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Exercise(M) | 35,333 | - | - | Direct |
| Jan 30, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 68,000 | - | - | Direct |
| Jan 30, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Award(A) Restricted Stock Unit | 34,000 | - | - | Direct |
| Dec 31, 2024 |  SHPH Shuttle Pharmaceuticals Holdings, Inc. | Award(A) | 209,790 | - | - | Direct |
| Dec 23, 2024 | SHPH Shuttle Pharmaceuticals Holdings, Inc. | Award(A) | 209,790 | - | - | Direct |
1-12 of 12 transactions
About Schafer Joshua
Schafer Joshua (SEC CIK 0001945557) files insider reports with the SEC as CCO of ZEVRA THERAPEUTICS, INC. (ZVRA) and Director of Shuttle Pharmaceuticals Holdings, Inc. (SHPH).
Signal8 holds 6 ownership filings by Schafer Joshua (4 Form 4, 2 Form 5), filed between Feb 3, 2025 and Feb 4, 2026. Those filings report 12 transactions, from Dec 23, 2024 to Feb 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Schafer Joshua's filings is in CELEBRATION, FL.
Recent filings by Schafer Joshua
- Feb 3, 2026: Open-market sale of ZVRA shares (Form 4, code S).
- Jan 31, 2026: Option exercise of ZVRA shares (Form 4, code M).
- Jan 30, 2026: Open-market sale of ZVRA shares (Form 4, code S).
- Jan 30, 2026: Option exercise of ZVRA shares (Form 4, code M).
- Jan 29, 2026: Grants or awards of ZVRA derivative securities (2 lines, Form 4, code A).
Other insiders filing for ZEVRA THERAPEUTICS, INC. (ZVRA)
- McFarlane Neil F., President and CEO
- Thompson Rahsaan, Chief Legal & Compliance
- Watton Corey Michael, Director
- FAVORITO TAMARA A, Director
- Secor Alicia, Director
- Calder Douglas W, Director